Subsidiary of Shanghai Fosun Pharmaceutical (600196.SH) obtains approval for clinical trial of 24-valent pneumonia vaccine.

Shanghai Fosun Pharmaceutical (600196.SH) announced that its controlling subsidiary, Fosun Pharma (Chengdu) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Fosun Antijin"), recently received approval from the National Medical Products Administration for the clinical trial of a 24-valent pneumococcal polysaccharide conjugate vaccine (application registration category: preventive biological products class 1.4; hereinafter referred to as "24-valent pneumococcal vaccine" or "the vaccine"). Fosun Antijin plans to conduct Phase I clinical trials of the vaccine in China (excluding the regions of Hong Kong, Macau, and Taiwan). The vaccine, developed independently by the group, is intended for the prevention of infectious diseases caused by pneumococcal serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. The vaccine uses the group's proprietary platform technology to combine polysaccharide antigens with carrier proteins, inducing T-cell-dependent immune responses against polysaccharides and immune memory in individuals aged 6 weeks and older.